Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $850 million aggregate principal amount of its 0.75% senior convertible notes due 2023. In addition, Davis Polk advised the counterparties to convertible note hedge and warrant transactions entered into in connection with the offering.
Headquartered in San Diego, California, DexCom, Inc. is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers.
The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon, counsel Jeffrey Gould and associate Xin (Anita) Guo. The equity derivatives team included partners Mark M. Mendez and Mark J. DiFiore and associate Jeffrey H. Smith. The tax team included partner Rachel D. Kleinberg and associate James Manzione. Associate Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.